Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced changes to the Management Board effective on January 1, 2022.
Stronger than projected headwind from COVID-19 effects with significantly increased patient excess mortality due to global spread of Delta variant
Fresenius Medical Care continues to execute on its growth strategy 2025 launched in October 2020.
Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, is investing an additional USD 25 million in the U.S. medical company Humacyte, Inc.
Fresenius Medical Care North America opens a new laboratory in Mississippi, USA. With 200,000-square-foot (19,000 square-meters), it is the company’s largest facility of this kind.